Patient-derived organoids in precision cancer medicine.

Autor:	Tong L; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Electronic address: le.tong@ki.se., Cui W; Chemical Biology Consortium Sweden, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden., Zhang B; Organcare (Shenzhen) Biotechnology Company, Shenzhen, China., Fonseca P; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Zhao Q; Organcare (Shenzhen) Biotechnology Company, Shenzhen, China., Zhang P; Organcare (Shenzhen) Biotechnology Company, Shenzhen, China., Xu B; Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China., Zhang Q; Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China., Li Z; Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China., Seashore-Ludlow B; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Yang Y; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Respiratory Medicine, The Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Zhejiang, China., Si L; Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China. Electronic address: ll.si@siat.ac.cn., Lundqvist A; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Electronic address: andreas.lundqvist@ki.se.
Jazyk:	angličtina
Zdroj:	Med (New York, N.Y.) [Med] 2024 Nov 08; Vol. 5 (11), pp. 1351-1377. Date of Electronic Publication: 2024 Sep 27.
DOI:	10.1016/j.medj.2024.08.010
Abstrakt:	Organoids are three-dimensional (3D) cultures, normally derived from stem cells, that replicate the complex structure and function of human tissues. They offer a physiologically relevant model to address important questions in cancer research. The generation of patient-derived organoids (PDOs) from various human cancers allows for deeper insights into tumor heterogeneity and spatial organization. Additionally, interrogating non-tumor stromal cells increases the relevance in studying the tumor microenvironment, thereby enhancing the relevance of PDOs in personalized medicine. PDOs mark a significant advancement in cancer research and patient care, signifying a shift toward more innovative and patient-centric approaches. This review covers aspects of PDO cultures to address the modeling of the tumor microenvironment, including extracellular matrices, air-liquid interface and microfluidic cultures, and organ-on-chip. Specifically, the role of PDOs as preclinical models in gene editing, molecular profiling, drug testing, and biomarker discovery and their potential for guiding personalized treatment in clinical practice are discussed. Competing Interests: Declaration of interests The authors declare no competing interests. (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu